搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
1 天
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...
FierceBiotech
1 天
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...
STAT
1 天
Metsera’s GLP-1 drug has potential for monthly dosing, new data show
Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.
BioSpace
1 天
New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss, Few Side Effects
Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...
ENDPOINTS NEWS
1 天
Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with ...
Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...
The Valdosta Daily Times
1 天
Metsera Reports Highly Competitive Results from Ongoing Trial of Novel, Potential Once ...
Metsera plans to initiate a Phase 2b trial of MET-097 in Q4 2024, with data anticipated in the first half of 2025.
28 天
on MSN
Why Weight-Loss Drugs Are Billion-Dollar Blockbusters: QuickTake
Obesity is among the world’s most common health conditions, but for years medicine had few effective approaches to offer ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈